ImmunityBio Inc Ordinary Shares IBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.45
- Day Range
- $7.26–7.79
- 52-Week Range
- $1.95–12.43
- Bid/Ask
- $7.67 / $7.69
- Shares Outstanding
- 1.05B
- Market Cap
- $8.04B
- Volume/Avg
- 9M / 13M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 52.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 691
- Website
- https://www.immunitybio.com
Valuation
|
Metric
|
IBRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 52.48 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IBRX
|
|---|---|
Quick Ratio | 6.24 |
Current Ratio | 6.67 |
Interest Coverage | −6.65 |
Quick Ratio
IBRX
Profitability
|
Metric
|
IBRX
|
|---|---|
Return on Assets (Normalized) | −133.17% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
IBRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%#@>p% | LOCK|VFvM | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|C%JrQ@Y | LOCK|!<tRD | $71B | |||
| argenx SE ADR
ARGX
| LOCK|%xFQWZn | LOCK|Wy | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|pYN%NWy | LOCK|z&C | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|CPC&#> | LOCK|YLwg | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>vcshTPt | LOCK|#z&% | $26B | |||
| Moderna Inc
MRNA
| LOCK|jlXH#K> | LOCK|mm | $25B | |||
| Incyte Corp
INCY
| LOCK|n<&bgK | LOCK|!>? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|K^>!Zg | LOCK|tM | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|nKvCp<r | LOCK|>#> | $16B |
United States